1035 Cambridge Street
Suite 18A
Cambridge, MA 02141
United States
212 582 1199
https://eternatx.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 8
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Ms. Sandra M. Gurrola | Principal Financial & Accounting Officer and Senior VP of Finance | 305,88k | N/D | 1967 |
Mr. Sanjeev Luther | CEO, President & Director | N/D | N/D | 1962 |
Ms. Dorothy J. Clarke | General Counsel & Director | N/D | N/D | 1966 |
Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
L'ISS Governance QualityScore di Eterna Therapeutics Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.